Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
153 enrolled
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
335 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
Phase 1 Recruiting
28 enrolled
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1 Recruiting
420 enrolled
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3 Recruiting
222 enrolled
Tazemetostat and Palbociclib With CPX-351for R/R AML
Phase 1 Recruiting
24 enrolled
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Phase 1 Recruiting
24 enrolled
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Phase 4 Recruiting
850 enrolled
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Phase 3 Recruiting
240 enrolled
QuANTUM-WILD
Phase 3 Recruiting
700 enrolled
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Phase 3 Recruiting
1,186 enrolled
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 Recruiting
128 enrolled
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 2 Recruiting
102 enrolled
Venetoclax AML
Phase 1 Recruiting
99 enrolled
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Recruiting
32 enrolled
AML-DS-2025
Phase 3 Recruiting
100 enrolled
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 Recruiting
240 enrolled
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Phase 2 Recruiting
172 enrolled
CAMS-Ph+ B-ALL
Phase 3 Recruiting
150 enrolled
CCCG-TALL-2025
Phase 2/3 Recruiting
610 enrolled
CCCG-LR-B-ALL
Phase 2/3 Recruiting
3,000 enrolled
MRD-positive AML Clinical Study
Phase NA Recruiting
120 enrolled
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Phase 2 Recruiting
50 enrolled
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Phase 2 Recruiting
100 enrolled
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 Recruiting
50 enrolled
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Phase 1/2 Recruiting
32 enrolled
BRALLA
Recruiting
180 enrolled
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3 Recruiting
5,000 enrolled
Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 Recruiting
22 enrolled
LBL 2018
Phase 3 Recruiting
683 enrolled
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3 Recruiting
50 enrolled
BIG-1
Phase 2/3 Recruiting
3,100 enrolled
Optimum Induction Therapy of Low-risk APL
Phase NA Recruiting
74 enrolled
VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/3 Recruiting
116 enrolled
Myechild01
Phase 3 Recruiting
700 enrolled